Patents - stay tuned to the technology

Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Chalcogen bonded directly to ring carbon of the thiazole ring

Subclass of:

548 - Organic compounds -- part of the class 532-570 series

548000000 - ORGANIC COMPOUNDS (CLASS 532, SUBCLASS 1)

548000000 - HETEROCYCLIC CARBON COMPOUNDS CONTAINING A HETERO RING HAVING CHALCOGEN (I.E., OXYGEN, SULFUR, SELENIUM, OR TELLURIUM) OR NITROGEN AS THE ONLY RING HETERO ATOMS (Class 540, subclass 1)

548100000 - Hetero ring is five-membered having two or more ring hetero atoms of which at least one is nitrogen (e.g., selenazoles, etc.)

548146000 - 1,3-thiazoles (including hydrogenated)

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
548182000 Chalcogen bonded directly to ring carbon of the thiazole ring 23
20090137817SPATIALLY-DEFINED MACROCYCLIC COMPOUNDS USEFUL FOR DRUG DISCOVERY - Novel spatially-defined macrocyclic compounds containing specific conformational control elements are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.05-28-2009
201001450632- thioethenyl substituted carbapenem derivatives - 2-Ethenylthio-type carbapenem derivatives of formula (I) or pharmaceutically acceptable salts thereof are provided. The compounds according to the present invention have potent antimicrobial activity and a wide antimicrobial spectrum against pneumococci including penicillin resistant 06-10-2010
548183000 Plural chalcogens bonded directly to ring carbons of the thiazole ring 7
20080293949Novel heterocyclic analogs of diphenylethylene compounds - Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.11-27-2008
20090023929Intermediate of 6-Substituted 1-Methyl-1-H-Benzimidazole Derivative and Method for Producing Same - A method for preparing a compound having the following formula (I)01-22-2009
20100222596KIND OF ORGANIC COMPOUND AND ORGANIC DYE USED IN DYE-SENSITIZED SOLAR CELL THEREOF - A kind of organic compound and organic dye used in dye-sensitized solar cell thereof. In the present invention, we synthesize a series of novel organic compounds with the structure of donor-conjugated chain-acceptor (D-π-A). The electron donor and acceptor groups, for example, are arylamine and cyanoacrylic acid, respectively. These novel organic compounds can be applied to the material of dye layer in the dye-sensitized solar cell (DSSC).09-02-2010
20100234612Intermediate of 6-substituted-1-methyl-1-H-benzimidazole derivative and method for producing same - A compound having the following formula (III)09-16-2010
20110160462CRYSTALLINE FORMS OF THIAZOLIDINEDIONE COMPOUND AND ITS MANUFACTURING METHOD - Thiazolidinedione compound crystalline forms useful as a bulk material for the manufacture of a peroxisome proliferator-activated receptor (PPAR) γ activator or an anticancer pharmaceutical composition are provided, which are hydrate crystalline forms of 5-(4-{[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1-H-benzimi dazol-2-yl]methoxy}benzyl)-1,3-thiazolidine-2,4-dione represented by Formula (I) below and of its dihydrochloride.06-30-2011
20130204008NOVEL SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS - The present invention provides novel methods for synthesizing PPARγ sparing compounds, e.g., thiazolidinediones, that are useful for preventing and/or treating metabolic disorders such as diabetes, obesity, hypertension, and inflammatory diseases.08-08-2013
20150051406PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES - The present invention relates to novel salts of thiazolidinediones and other pharmaceutical agents that are useful for treating and/or preventing metabolic diseases (e.g., diabetes, or neurodegenerative diseases (e.g., Alzheimer's Disease).02-19-2015
548184000 Nitrogen attached directly to the thiazole ring by nonionic bonding 9
20100280255PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES - The present invention relates to methods of making compounds that inhibit 11-hydroxysteroid dehydrogenase type 1 enzyme (11-HSD1). One method comprises (a) contacting a compound of formula (II) sequentially with a chiral base in the presence of an amine, and an alkylating agent R3-LG, (b) contacting the product of (a) with an acid to form a salt, and (c) reacting the salt with a base to form the compound of formula (I), wherein Z, R1, R2, and R3 are defined herein.11-04-2010
20100317867NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES - The present invention relates to a new process for the preparation of 2-imino-thiazolidin-4-one compounds of the Formula (I) and (II) and to compounds of Formula (II) as such. The present compounds of Formula (II) can be used as intermediates in the preparation of thiazolidin-4-one derivatives of the General Formula (II), said derivatives being described in WO 2005/054215. These compounds of General Formula (II) are described in WO 2005/054215 to act as immunosuppressive agents.12-16-2010
20110160463PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES - The present invention relates to methods of making compounds that inhibit 11-β-hydroxysteroid dehydrogenase type 1 enzyme (11-β HSD1). One method comprises (a) contacting a compound of formula (II) with a chiral base, deprotonating agent, and an alkylating agent R06-30-2011
20110178307ASYMMETRIC PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES - The invention provides two process for synthesizing substituted aminothiazolone compounds as inhibitors of 11-β-hydroxy steroid dehydrogenase type 1. The processes allow the stereoselective synthesis of the desired compounds without the use of stoichiometric amounts of chiral catalysts.07-21-2011
20120302758NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES - The present invention relates to a new process for the preparation of 2-imino-thiazolidin-4-one compounds of the Formula (I) and (II) and to compounds of Formula (II) as such. The present compounds of Formula (II) can be used as intermediates in the preparation of thiazolidin-4-one derivatives of the General Formula (II), said derivatives being described in WO 2005/054215. These compounds of General Formula (II) are described in WO 2005/054215 to act as immunosuppressive agents.11-29-2012
20130345432ASYMMETRIC PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES - The invention provides two process for synthesizing substituted aminothiazolone compounds as inhibitors of 11-β-hydroxy steroid dehydrogenase type 1. The processes allow the stereoselective synthesis of the desired compounds without the use of stoichiometric amounts of chiral catalysts.12-26-2013
20140316140DOSING REGIMEN FOR A SELECTIVE S1P1 AGONIST - The present invention relates to a dosing regimen for a selective S1P10-23-2014
20150336912(4E)-4-(4-SUBSTITUTED BENZYLIDENEAMINO)-2,3-DIHYDRO-3-SUBSTITUTED-2-THIOXOTHIAZOLE-5-CARBONITRI- LES AS A2AR ANTAGONIST AND PROCESS FOR PREPARATION THEREOF - The present invention provides (4E)-4-(4-substituted benzylideneamino)-2,3-dihydro-3-substituted-2-thioxothiazole-5-carbonitriles of general formula A, below, and a process for the preparation thereof.11-26-2015
548185000 Having -C(=X)-, wherein X is chalcogen, bonded directly to nitrogen 1
20090176991BENZAMIDE GLUCOKINASE ACTIVATORS - The present invention relates to N-heteroaryl-benzamides of the formula (I), pharmaceutical compositions comprising the same, and methods of using the same. The N-heteroaryl-benzamides are useful as glucokinase activators.07-09-2009
548186000 Chalcogen attached indirectly to the thiazole ring by nonionic bonding 4
20110237803Process - A process for preparing the S or R enantiomer of a compound of formula A,09-29-2011
548187000 The chalcogen, X, is in a -C(=X)- group 3
548188000 The -C(=X)- group is bonded directly to the thiazole ring 3
20080269498THERAPEUTIC SUBSTITUTED LACTAMS - Therapeutic compounds, compositions, medicaments, and methods are disclosed herein.10-30-2008
20080287683PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES - The present invention is directed to practical high-yielding synthetic processes for preparing 3,4-disubstituted-thiazolidin-2-ones, which do not compromise the absolute stereochemical integrity of the compounds. The present invention is also directed to novel compounds of 3,4-disubstituted-thiazolidin-2-ones. The compounds prepared by the present invention are useful in the synthesis and manufacture of compounds (such as latrunculins and/or their analogs) for treating diseases or conditions associated with inhibiting actin polymerization.11-20-2008
20160083341METHOD FOR PRODUCING a-SUBSTITUTED CYSTEINE OR SALT THEREOF OR SYNTHETIC INTERMEDIATE OF a-SUBSTITUTED CYSTEINE - According to the present invention, it becomes possible to perform a process for converting into an α-substituted cysteine represented by general formula (1) or a salt thereof at low cost and on an industrial scale by employing a process that is routed through a compound represented by general formula (3) to a compound represented by general formula (6). Particularly, by employing a process that is routed through a compound represented by general formula (7-2), it becomes possible to detach a tert-butyl protection group in a simple manner and to produce the compound represented by general formula (1) with high purity. Furthermore, by employing a process that is routed through tert-butylthiomethanol or a process that is routed through a compound represented by general formula (9), it becomes possible to produce a compound represented by general formula (2) without generating bischloromethylether that is an oncogenic substance. In the production of an α-substituted-D-cysteine or a salt thereof, it becomes possible to perform a process for converting the compound represented by general formula (2) into a compound represented by general formula (3S) in one step by allowing an enzyme or the like to act on the compound represented by general formula (2).03-24-2016
548189000 Nitrogen attached indirectly to the thiazole ring by nonionic bonding 1
20160016943BENZOTHIAZOLE DERIVATIVES AND A USE THEREOF FOR THE TREATMENT OF CANCER - Provided are a compound represented by Formula I, a pharmaceutically acceptable salt thereof, or a solvate thereof; and a pharmaceutical composition for cancer treatment and a pharmaceutical composition for a radiation sensitizer for cancer treatment, each pharmaceutical composition including the compound of Formula I, the pharmaceutically acceptable salt thereof, or the solvate thereof:01-21-2016
Website © 2025 Advameg, Inc.